Biotech Showcase™ 2016: Interview: Q BioMed accelerates advances in vascular therapeutics

February 24, 2016
Ensuring that all the necessary resources are in place to build a sustainable business is a key challenge for most entrepreneurs. They need access to capital and expertise without having to give it away cheaply. Q BioMed Inc CEO Denis Corin explains to Mike Ward, global director of content for Informa’s pharma insight products, how his biomedical acceleration and development company is providing target companies and assets access to strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential. The company is agnostic in terms of geography, therapeutic focus, or development phase. One of Q BioMed’s recent acquisitions was Mannin Research Inc., a biotech that is developing a new class of vascular therapeutics and led Dr. Susan E. Quaggin, chief of the division of nephrology and director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago. The primary target indication is for a first-in-class therapeutic eyedrop for the treatment of glaucoma in adults and children. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: F-star CEO details asset-centric ambitions
Biotech Showcase™ 2016: Interview: F-star CEO details asset-centric ambitions

Unveiling its second asset-centric deal, F-star CEO Dr. John Haurum reveals to Mike Ward, global director o...

Next Video
Biotech Showcase™ 2016: Interview: Whole genome sequencing in 25 minutes with Edico Genome
Biotech Showcase™ 2016: Interview: Whole genome sequencing in 25 minutes with Edico Genome

Within 10 years, genomics is going to account for the biggest big data challenge. Dr. Pieter van Rooyen, pr...